Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus. J of Skin [Internet]. 2023 Jul. 17 [cited 2025 May 30];7(4):s226. Available from: https://skin.dermsquared.com/skin/article/view/2193